SANOFI-AVENTIS (EPA:SAN) Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
Transparency directive : regulatory news
27/06/2023 07:30